Overview of Recent Clinical Pharmacokinetic Studies with Acitretin (Ro 10-1670, Etretin)
- 1 January 1989
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 178 (2), 79-87
- https://doi.org/10.1159/000248397
Abstract
Following oral administration of acitretin with food, peak plasma concentrations of unchanged drug (Ro 10-1670) are reached within 4 h. The mean absolute bioavailabihty of acitretin is 59% with high interpatient variability consistent with that of etretinate. Taking acitretin with food results in an increased and more consistent bioavailabihty. The drug appears to be extensively distributed throughout the body without unexpected accumulation and the elimination half-life is approximately 50 h. Acitretin has a profound pharmacokinetic advantage over etretinate because it is eliminated more rapidly from the body; etretinate is sequestered into fatty tissue due to its greater lipophilicity creating a deep compartment from which it is only slowly released. Acitretin is eliminated entirely by the metabolism and the resultant metabolites are excreted via the kidney and bile.This publication has 6 references indexed in Scilit:
- Residual Plasma Concentrations of Acitretin (Ro 101670) and Its Metabolite (Ro 13–7652) after Chronic AdministrationDermatology, 1988
- Etretinate Pharmacokinetics in Chronic Renal FailureDermatology, 1986
- Tissue distribution of aromatic retinoid (etretinate) in three autopsy cases: drug accumulation in adrenals and fatActa Dermato-Venereologica, 1986
- Effect of Meals on the Kinetics of EtretinateThe Journal of Clinical Pharmacology, 1985
- Etretinate kinetics during chronic dosing in severe psoriasisClinical Pharmacology & Therapeutics, 1985
- Determination of etretinate and its main metabolite in human plasma using normal-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1983